Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.

Limbach K, Stefaniak M, Chen P, Patterson NB, Liao G, Weng S, Krepkiy S, Ekberg G, Torano H, Ettyreddy D, Gowda K, Sonawane S, Belmonte A, Abot E, Sedegah M, Hollingdale MR, Moormann A, Vulule J, Villasante E, Richie TL, Brough DE, Bruder JT.

Malar J. 2017 Jul 3;16(1):263. doi: 10.1186/s12936-017-1911-z.

2.

Cellular immune response to DNA and vaccinia prime-boost immunization kills Plasmodium yoelii-infected hepatocytes in vitro.

Sacci JB Jr, Hollingdale MR, Sedegah M.

Pathog Dis. 2017 Jun 1;75(4). doi: 10.1093/femspd/ftx051.

PMID:
28475711
3.

Correction: Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes.

Sedegah M, Peters B, Hollingdale MR, Ganeshan HD, Huang J, Farooq F, Belmonte MN, Belmonte AD, Limbach KJ, Diggs C, Soisson L, Chuang I, Villasante ED.

PLoS One. 2016 Dec 20;11(12):e0168952. doi: 10.1371/journal.pone.0168952. eCollection 2016.

4.

Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes.

Sedegah M, Peters B, Hollingdale MR, Ganeshan HD, Huang J, Farooq F, Belmonte MN, Belmonte AD, Limbach KJ, Diggs C, Soisson L, Chuang I, Villasante ED.

PLoS One. 2016 Oct 3;11(10):e0163026. doi: 10.1371/journal.pone.0163026. eCollection 2016. Erratum in: PLoS One. 2016 Dec 20;11(12 ):e0168952.

5.

Development of replication-deficient adenovirus malaria vaccines.

Hollingdale MR, Sedegah M, Limbach K.

Expert Rev Vaccines. 2017 Mar;16(3):261-271. doi: 10.1080/14760584.2016.1228454. Epub 2016 Sep 8. Review.

PMID:
27606709
6.

Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity.

Hickey BW, Lumsden JM, Reyes S, Sedegah M, Hollingdale MR, Freilich DA, Luke TC, Charoenvit Y, Goh LM, Berzins MP, Bebris L, Sacci JB Jr, De La Vega P, Wang R, Ganeshan H, Abot EN, Carucci DJ, Doolan DL, Brice GT, Kumar A, Aguiar J, Nutman TB, Leitman SF, Hoffman SL, Epstein JE, Richie TL.

Malar J. 2016 Jul 22;15(1):377. doi: 10.1186/s12936-016-1435-y.

7.

Development of whole sporozoite malaria vaccines.

Hollingdale MR, Sedegah M.

Expert Rev Vaccines. 2017 Jan;16(1):45-54. Epub 2016 Jul 18. Review.

PMID:
27327875
8.

Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria.

Ganeshan H, Kusi KA, Anum D, Hollingdale MR, Peters B, Kim Y, Tetteh JK, Ofori MF, Gyan BA, Koram KA, Huang J, Belmonte M, Banania JG, Dodoo D, Villasante E, Sedegah M.

Malar J. 2016 Feb 1;15:55. doi: 10.1186/s12936-016-1098-8.

9.

Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development.

Aguiar JC, Bolton J, Wanga J, Sacci JB, Iriko H, Mazeika JK, Han ET, Limbach K, Patterson NB, Sedegah M, Cruz AM, Tsuboi T, Hoffman SL, Carucci D, Hollingdale MR, Villasante ED, Richie TL.

PLoS One. 2015 Aug 20;10(8):e0136109. doi: 10.1371/journal.pone.0136109. eCollection 2015.

10.

Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.

Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Huang J, Abot E, Limbach K, Chuang I, Tamminga C, Epstein JE, Villasante E.

Hum Vaccin Immunother. 2015;11(11):2705-15. doi: 10.1080/21645515.2015.1019186. Epub 2015 Aug 20.

11.

Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.

Anum D, Kusi KA, Ganeshan H, Hollingdale MR, Ofori MF, Koram KA, Gyan BA, Adu-Amankwah S, Badji E, Huang J, Belmonte M, Banania GJ, Kwofie TB, Villasante E, Dodoo D, Sedegah M.

Malar J. 2015 Jan 21;14:20. doi: 10.1186/s12936-014-0539-5.

12.

Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes.

Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Kim Y, Peters B, Sette A, Huang J, McGrath S, Abot E, Limbach K, Shi M, Soisson L, Diggs C, Chuang I, Tamminga C, Epstein JE, Villasante E, Richie TL.

PLoS One. 2014 Sep 11;9(9):e106241. doi: 10.1371/journal.pone.0106241. eCollection 2014.

13.

Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.

Tamminga C, Sedegah M, Maiolatesi S, Fedders C, Reyes S, Reyes A, Vasquez C, Alcorta Y, Chuang I, Spring M, Kavanaugh M, Ganeshan H, Huang J, Belmonte M, Abot E, Belmonte A, Banania J, Farooq F, Murphy J, Komisar J, Richie NO, Bennett J, Limbach K, Patterson NB, Bruder JT, Shi M, Miller E, Dutta S, Diggs C, Soisson LA, Hollingdale MR, Epstein JE, Richie TL.

Hum Vaccin Immunother. 2013 Oct;9(10):2165-77. doi: 10.4161/hv.24941. Epub 2013 Jun 4.

14.

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).

Sedegah M, Kim Y, Ganeshan H, Huang J, Belmonte M, Abot E, Banania JG, Farooq F, McGrath S, Peters B, Sette A, Soisson L, Diggs C, Doolan DL, Tamminga C, Villasante E, Hollingdale MR, Richie TL.

Malar J. 2013 Jun 5;12:185. doi: 10.1186/1475-2875-12-185.

15.

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. Epub 2013 Feb 14.

16.

Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, Luke TC, Freilich DA, Aguiar JC, Sacci JB Jr, Sedegah M, Nosek RA Jr, De La Vega P, Berzins MP, Majam VF, Abot EN, Ganeshan H, Richie NO, Banania JG, Baraceros MF, Geter TG, Mere R, Bebris L, Limbach K, Hickey BW, Lanar DE, Ng J, Shi M, Hobart PM, Norman JA, Soisson LA, Hollingdale MR, Rogers WO, Doolan DL, Hoffman SL.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1564-84. doi: 10.4161/hv.22129. Epub 2012 Nov 1.

17.

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.

Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, Steinbeiss V, Fedders C, Smith K, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Murphy J, Komisar J, Williams J, Shi M, Brambilla D, Manohar N, Richie NO, Wood C, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Diggs C, Soisson L, Carucci D, Levine G, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2011;6(10):e25868. doi: 10.1371/journal.pone.0025868. Epub 2011 Oct 7.

18.

Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.

Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Manohar N, Richie NO, Wood C, Long CA, Regis D, Williams FT, Shi M, Chuang I, Spring M, Epstein JE, Mendoza-Silveiras J, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Soisson L, Diggs C, Carucci D, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2011;6(10):e24586. doi: 10.1371/journal.pone.0024586. Epub 2011 Oct 7.

19.

Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.

Dodoo D, Hollingdale MR, Anum D, Koram KA, Gyan B, Akanmori BD, Ocran J, Adu-Amankwah S, Geneshan H, Abot E, Legano J, Banania G, Sayo R, Brambilla D, Kumar S, Doolan DL, Rogers WO, Epstein J, Richie TL, Sedegah M.

Malar J. 2011 Jun 20;10:168. doi: 10.1186/1475-2875-10-168.

20.

Plasmodium falciparum liver stage antigen-1 is cross-linked by tissue transglutaminase.

Nicoll WS, Sacci JB, Rodolfo C, Di Giacomo G, Piacentini M, Holland ZJ, Doerig C, Hollingdale MR, Lanar DE.

Malar J. 2011 Jan 21;10:14. doi: 10.1186/1475-2875-10-14.

21.

Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.

Sedegah M, Kim Y, Peters B, McGrath S, Ganeshan H, Lejano J, Abot E, Banania G, Belmonte M, Sayo R, Farooq F, Doolan DL, Regis D, Tamminga C, Chuang I, Bruder JT, King CR, Ockenhouse CF, Faber B, Remarque E, Hollingdale MR, Richie TL, Sette A.

Malar J. 2010 Aug 24;9:241. doi: 10.1186/1475-2875-9-241.

22.

Field trial of five repellent formulations against mosquitoes in Ahero, Kenya.

Sherwood V, Kioko E, Kasili S, Ngumbi P, Hollingdale MR.

US Army Med Dep J. 2009 Jul-Sep:60-5.

PMID:
20084738
23.

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpetch A, Stewart VA, Lanar DE, Dutta S, Angov E, Ware LA, Bergmann-Leitner ES, House B, Voss G, Dubois MC, Cohen JD, Fukuda MM, Heppner DG, Miller RS.

Vaccine. 2009 Dec 11;28(2):452-62. doi: 10.1016/j.vaccine.2009.10.022. Epub 2009 Oct 24.

PMID:
19857448
24.

Functional immunoassays using an in-vitro malaria liver-stage infection model: where do we go from here?

House BL, Hollingdale MR, Sacci JB Jr, Richie TL.

Trends Parasitol. 2009 Nov;25(11):525-33. doi: 10.1016/j.pt.2009.08.004. Epub 2009 Sep 9. Review.

PMID:
19747878
26.

Age-dependent enhancement of IFN-gamma responses to Plasmodium falciparum liver stage antigen-1 T cell epitopes.

Bongartz M, Rezbach P, Borrmann S, Hollingdale MR, Kremsner PG, Luty AJ.

Parasitol Res. 2002 Dec;88(12):1083-9. Epub 2002 Aug 21.

PMID:
12444460
27.
28.

Immune responses to liver-stage parasites: implications for vaccine development.

Hollingdale MR, Krzych U.

Chem Immunol. 2002;80:97-124. Review. No abstract available.

PMID:
12058653
29.

Plasmodium falciparum liver-stage antigen-1 peptide-specific interferon-gamma responses are not suppressed during uncomplicated malaria in African children.

Luty AJ, Bongartz M, Rezbach P, Faucher JF, Hollingdale MR, Kremsner PG.

Eur Cytokine Netw. 2001 Oct-Dec;12(4):647-53.

30.
31.

Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine.

Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE.

Trends Parasitol. 2001 May;17(5):219-23.

PMID:
11323304
32.
33.

Expression of TetC fusion proteins from Salmonella in a gaseous environment that models conditions found in mammalian tissues.

Heal KG, McConkey GA, Hormaeche CE, Hollingdale MR, Khan CM, Taylor-Robinson AW.

Biotechniques. 2000 Feb;28(2):228-30, 232. No abstract available.

PMID:
10683729
34.

Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids.

Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW.

Vaccine. 1999 Sep;18(3-4):251-8.

PMID:
10506649
35.

Identification of heparin as a ligand for the A-domain of Plasmodium falciparum thrombospondin-related adhesion protein.

McCormick CJ, Tuckwell DS, Crisanti A, Humphries MJ, Hollingdale MR.

Mol Biochem Parasitol. 1999 May 15;100(1):111-24.

PMID:
10376999
36.

Biology of malarial liver stages: implications for vaccine design.

Hollingdale MR, McCormick CJ, Heal KG, Taylor-Robinson AW, Reeve P, Boykins R, Kazura JW.

Ann Trop Med Parasitol. 1998 Jun;92(4):411-7. Review.

PMID:
9683893
37.

T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic.

Connelly M, King CL, Bucci K, Walters S, Genton B, Alpers MP, Hollingdale M, Kazura JW.

Infect Immun. 1997 Dec;65(12):5082-7.

38.

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Tine JA, Lanar DE, Smith DM, Wellde BT, Schultheiss P, Ware LA, Kauffman EB, Wirtz RA, De Taisne C, Hui GS, Chang SP, Church P, Hollingdale MR, Kaslow DC, Hoffman S, Guito KP, Ballou WR, Sadoff JC, Paoletti E.

Infect Immun. 1996 Sep;64(9):3833-44.

39.

T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens.

Krzych U, Lyon JA, Jareed T, Schneider I, Hollingdale MR, Gordon DM, Ballou WR.

J Immunol. 1995 Oct 15;155(8):4072-7.

PMID:
7561118
40.

Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast.

Moelans II, Cohen J, Marchand M, Molitor C, de Wilde P, van Pelt JF, Hollingdale MR, Roeffen WF, Eling WM, Atkinson CT, et al.

Mol Biochem Parasitol. 1995 Jun;72(1-2):179-92.

PMID:
8538688
41.

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, et al.

J Infect Dis. 1995 Jun;171(6):1576-85.

PMID:
7769295
42.

Characterization of a sporozoite antigen common to Plasmodium falciparum and Plasmodium berghei.

Sina BJ, Wright C, Atkinson CT, Ballou R, Aikawa M, Hollingdale M.

Mol Biochem Parasitol. 1995 Feb;69(2):239-46.

PMID:
7770087
43.

Ultrastructural localization of CD36 in human hepatic sinusoidal lining cells, hepatocytes, human hepatoma (HepG2-A16) cells, and C32 amelanotic melanoma cells.

Maeno Y, Fujioka H, Hollingdale MR, Ockenhouse CF, Nakazawa S, Aikawa M.

Exp Parasitol. 1994 Nov;79(3):383-90.

PMID:
7525338
44.
45.

Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites.

Edelman R, Hoffman SL, Davis JR, Beier M, Sztein MB, Losonsky G, Herrington DA, Eddy HA, Hollingdale MR, Gordon DM, et al.

J Infect Dis. 1993 Oct;168(4):1066-70.

PMID:
8376823
46.

Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes.

White K, Krzych U, Gordon DM, Porter TG, Richards RL, Alving CR, Deal CD, Hollingdale M, Silverman C, Sylvester DR, et al.

Vaccine. 1993 Oct;11(13):1341-6.

PMID:
7507624
47.

Plasmodium falciparum sporozoite immunization protects against Plasmodium berghei sporozoite infection.

Sina BJ, do Rosario VE, Woollett G, Sakhuja K, Hollingdale MR.

Exp Parasitol. 1993 Sep;77(2):129-35.

PMID:
8375482
48.

Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites.

Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM.

Am J Trop Med Hyg. 1993 Aug;49(2):166-73.

PMID:
8357078
50.

Sporozoite invasion.

Hollingdale MR, Sinden RE, van Pelt J.

Nature. 1993 Mar 4;362(6415):26. No abstract available.

PMID:
8446167

Supplemental Content

Loading ...
Support Center